Genetic test to match treatment for advanced kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study looks at genetic (RNA) testing of kidney cancer tissue to help choose the best drug treatment. It may help guide therapy for people with advanced or metastatic clear cell kidney cancer who are starting treatment for the first time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have kidney cancer (clear cell type) confirmed by pathology (biopsy/surgery tissue results).
- Your cancer is advanced or has spread (metastatic) and cannot be cured with surgery or radiation.
- You have not had any drug treatment for kidney cancer before in the advanced/metastatic setting.
- Your scans show at least one measurable spot the doctors can track on treatment.
- You can provide tumor tissue for RNA testing, and it must come from suitable soft tissue around bone (bone-only tissue is not accepted).
- Your general health is good enough (Karnofsky performance score of 70% or higher), and your blood tests and organ function meet limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests whether adding a probiotic (CBM588) to a standard immunotherapy combination (nivolumab and ipilimumab) helps treat advanced kidney cancer. It is for people with a specific type of kidney cancer that has spread or cannot be removed with surgery, who have not had systemic treatment before.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests an experimental therapy using special immune cells engineered to target a protein called CD70 on kidney cancer cells. It may help patients whose cancer has returned or spread after previous treatment.
This trial tests whether adding a biotherapy (a special drug from a living source) or a placebo to standard treatments helps people with advanced kidney cancer. It may be a good option if your cancer hasn't been treated yet and you are in fairly good health.
This trial tests two combinations of investigational drugs for people with advanced clear cell kidney cancer that cannot be removed with surgery. The goal is to see if these combinations can shrink or control the cancer.
Hear when a new Advanced Clear Cell Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.